KR20060134041A - 음식물 섭취 관리 방법 - Google Patents

음식물 섭취 관리 방법 Download PDF

Info

Publication number
KR20060134041A
KR20060134041A KR1020067015532A KR20067015532A KR20060134041A KR 20060134041 A KR20060134041 A KR 20060134041A KR 1020067015532 A KR1020067015532 A KR 1020067015532A KR 20067015532 A KR20067015532 A KR 20067015532A KR 20060134041 A KR20060134041 A KR 20060134041A
Authority
KR
South Korea
Prior art keywords
agonist
subject
group
administering
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067015532A
Other languages
English (en)
Korean (ko)
Inventor
니어 바라크
Original Assignee
모르 리서치 애플리케이션즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL16159504A external-priority patent/IL161595A0/xx
Application filed by 모르 리서치 애플리케이션즈 리미티드 filed Critical 모르 리서치 애플리케이션즈 리미티드
Publication of KR20060134041A publication Critical patent/KR20060134041A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020067015532A 2004-04-22 2005-04-21 음식물 섭취 관리 방법 Ceased KR20060134041A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL16159504A IL161595A0 (en) 2004-04-22 2004-04-22 Betahistine as a weight management agent
IL161595 2004-04-22
US67029005P 2005-04-12 2005-04-12
US60/670,290 2005-04-12

Publications (1)

Publication Number Publication Date
KR20060134041A true KR20060134041A (ko) 2006-12-27

Family

ID=35197421

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067015532A Ceased KR20060134041A (ko) 2004-04-22 2005-04-21 음식물 섭취 관리 방법

Country Status (10)

Country Link
US (5) US7737165B2 (https=)
EP (1) EP1737454A4 (https=)
JP (1) JP2007533733A (https=)
KR (1) KR20060134041A (https=)
BR (1) BRPI0506807A (https=)
CA (1) CA2553309A1 (https=)
EA (1) EA200601414A1 (https=)
IL (1) IL176793A0 (https=)
NO (1) NO20063221L (https=)
WO (1) WO2005101979A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190116341A (ko) * 2017-02-02 2019-10-14 오토라눔 아게 베타히스틴을 포함하는 비강내 조성물

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
UA98938C2 (ru) * 2006-06-16 2012-07-10 Теракос, Инк. Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
JP5513378B2 (ja) * 2007-06-15 2014-06-04 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 治療化合物
KR101621726B1 (ko) 2008-05-27 2016-05-17 더 유니버시티 오브 멜버른 유스타키오관 기능장애 치료용 국소 약학적 조성물
US20120115778A1 (en) * 2009-07-15 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2
US20110021507A1 (en) * 2009-07-22 2011-01-27 Theracos, Inc. Inhibiting antipsychotic-induced weight gain
JP2013507713A (ja) * 2009-10-13 2013-03-04 ネステク ソシエテ アノニム 食物摂取を評定するシステム及びそのシステムを使用する方法
TR201908514T4 (tr) 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
US20110143704A1 (en) 2009-12-14 2011-06-16 William Lorentz Specialized dial a chip
US8778960B2 (en) * 2010-08-23 2014-07-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US20140072936A1 (en) * 2012-09-07 2014-03-13 Patrick D. Herron Method of Tracking Consumption and Associated Effects
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
RU2540911C2 (ru) * 2013-06-11 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами
DE102015202695A1 (de) * 2015-02-13 2016-08-18 Carl Zeiss Smt Gmbh Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
KR20250154480A (ko) * 2023-02-28 2025-10-28 바이오하벤 테라퓨틱스 리미티드 강박 관련 장애, 틱 장애 및 글루타메이트 흥분독성 관련 장애의 치료 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577871A (en) * 1976-05-28 1980-10-29 Unimed Inc Prevention of myocardial infarction
JPS55154915A (en) * 1979-05-21 1980-12-02 Jiyan Sadeia Shieruki Medicine mold
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
DE69939027D1 (de) * 1998-12-23 2008-08-14 Maxim Pharm Inc Synthese von histamin-dihydrochlorid
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
IT1309591B1 (it) 1999-03-05 2002-01-24 Formenti Farmaceutici Spa Composizioni a rilascio controllato di betaistina.
WO2000071106A2 (en) * 1999-05-19 2000-11-30 Astrazeneca Ab Method of treating weight gain
WO2001066081A2 (de) * 2000-03-08 2001-09-13 Awd.Pharma Gmbh & Co.Kg Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
WO2002087556A2 (en) 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
AU2003266165A1 (en) 2002-09-13 2004-04-30 Hossein Dovlatabadi Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
US20060039867A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190116341A (ko) * 2017-02-02 2019-10-14 오토라눔 아게 베타히스틴을 포함하는 비강내 조성물

Also Published As

Publication number Publication date
US20080004322A1 (en) 2008-01-03
WO2005101979A3 (en) 2006-07-27
WO2005101979A2 (en) 2005-11-03
EP1737454A2 (en) 2007-01-03
US20060073217A1 (en) 2006-04-06
CA2553309A1 (en) 2005-11-03
US7737165B2 (en) 2010-06-15
US20080004324A1 (en) 2008-01-03
EP1737454A4 (en) 2007-08-08
US20060084686A1 (en) 2006-04-20
IL176793A0 (en) 2006-10-31
BRPI0506807A (pt) 2007-05-29
JP2007533733A (ja) 2007-11-22
NO20063221L (no) 2006-10-06
US20080051439A1 (en) 2008-02-28
EA200601414A1 (ru) 2007-02-27

Similar Documents

Publication Publication Date Title
KR20060134041A (ko) 음식물 섭취 관리 방법
US9700548B2 (en) Antihistamines combined with dietary supplements for improved health
CN102083430B (zh) 大麻类化合物组合物在制备治疗脑部肿瘤药物中的用途
US7834056B2 (en) Pharmaceutical composition for gout
US20100152161A1 (en) Compositions for weight management
JP6762312B2 (ja) 過剰な体脂肪の治療処置または美容処置のためのｎｋ−３受容体拮抗薬
JP2002541097A (ja) 線維筋痛症及び関連症状の治療におけるフルピルチン
JPH05507731A (ja) 物質乱用障害の治療用医薬組成物
CN102395275A (zh) 用四环吡嗪并吲哚治疗多发性硬化症的方法
US20220133741A1 (en) AAntihistamines In Combination With A Range Of Substances For Improved Health
KR101971412B1 (ko) 정맥 내 투여용 이부프로펜의 투여
WO1998024411A2 (en) Method for oral administration of buspirone
PT1397128E (pt) Agonista opiáceo kapa para o tratamento de doenças da bexiga irritável.
JP2026505506A (ja) 癌を処置するためのｔｅａｄ及びｋｒａｓ ｇ１２ｄ阻害剤の組み合わせ
US20080051440A1 (en) Compositions for weight management
Shaila et al. A review of ketorolac as a potential therapeutic agent
US20240284941A1 (en) Antihistamines combined with dietary supplements for improved health
ZA200605724B (en) Method of food intake management
MXPA06007693A (en) Method of food intake management
AU2006202950A1 (en) Methods and Compositions for Weight Management
WO2024206147A1 (en) Dosage regimens of estrogen receptor degraders
JP2006076945A (ja) 線維筋痛症候群の治療剤
Bouchard et al. Couteracting 5htp causing lower Dopamine levels
WO2008063556A2 (en) Nornicotine for the treatment of pain

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060731

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100419

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20111012

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120504

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20111012

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I